Abstract
Ion channels are at present the third biggest target class in drug discovery. Primary research is continually uncovering potential new ion channel targets in indications such as cancer, diabetes and respiratory diseases, as well as the more established fields of pain, cardiovascular disease, and neurological disorders. Despite the physiological significance and therapeutic relevance in a wide variety of biological systems, ion channels still remain under exploited as drug targets. This is to a large extent resulting from the historical lack of screening technologies to provide the throughput and quality of data required to support medicinal chemistry. Although technical challenges still lie ahead, this historic bottleneck in ion channel drug discovery is now being overcome by novel technologies that can be integrated into lead generation stages of ion channel drug discovery to allow the development of novel therapeutic agents. This review describes the variety of technologies available for ion channel screening and discusses the opportunities these technologies provide. The challenges that remain to be addressed are highlighted.
Keywords: Ion channels, targets, drug discovery, screening technologies, automated electrophysiology platforms, fluorescence dye assays, ion flux assays
CNS & Neurological Disorders - Drug Targets
Title: Ion Channel Screening Technology
Volume: 7 Issue: 2
Author(s): Michael A. Dabrowski, Kim Dekermendjian, Per-Eric Lund, Johannes J. Krupp, Jon Sinclair and Olof Larsson
Affiliation:
Keywords: Ion channels, targets, drug discovery, screening technologies, automated electrophysiology platforms, fluorescence dye assays, ion flux assays
Abstract: Ion channels are at present the third biggest target class in drug discovery. Primary research is continually uncovering potential new ion channel targets in indications such as cancer, diabetes and respiratory diseases, as well as the more established fields of pain, cardiovascular disease, and neurological disorders. Despite the physiological significance and therapeutic relevance in a wide variety of biological systems, ion channels still remain under exploited as drug targets. This is to a large extent resulting from the historical lack of screening technologies to provide the throughput and quality of data required to support medicinal chemistry. Although technical challenges still lie ahead, this historic bottleneck in ion channel drug discovery is now being overcome by novel technologies that can be integrated into lead generation stages of ion channel drug discovery to allow the development of novel therapeutic agents. This review describes the variety of technologies available for ion channel screening and discusses the opportunities these technologies provide. The challenges that remain to be addressed are highlighted.
Export Options
About this article
Cite this article as:
Dabrowski A. Michael, Dekermendjian Kim, Lund Per-Eric, Krupp J. Johannes, Sinclair Jon and Larsson Olof, Ion Channel Screening Technology, CNS & Neurological Disorders - Drug Targets 2008; 7 (2) . https://dx.doi.org/10.2174/187152708784083867
DOI https://dx.doi.org/10.2174/187152708784083867 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Big Data Mining for CNS Diseases Analysis and Treatment: Focusing on Drug Target Discovery
Central nervous system (CNS) diseases, including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, represent a major global health challenge. Despite significant research efforts, the complexity and multifactorial nature of these diseases hinder the development of effective treatments. The rise of big data analytics and high-throughput technologies ...read more
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently, there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system and neurological disorders. The purpose ...read more
Innovative Therapeutics in Demyelinating CNS- Disorders: Immune Modulation, Antibody Therapy, Kinase Inhibition and Remyeliation Strategies
Demyelinating disorders, particularly multiple sclerosis represent chronic disease characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. This thematic issue will present a comprehensive overview of novel therapeutic advances targeting these processes. In addition to dissecting the roles of innate versus adaptive immunity, antibody therapies, and tyrosine kinase ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Purinergic Signaling and its Role in the Stem Cell Differentiation
Mini-Reviews in Medicinal Chemistry Contribution of Inflammatory Processes to Nerve Cell Toxicity by Bilirubin and Efficacy of Potential Therapeutic Agents
Current Pharmaceutical Design Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Membrane Estrogen Receptors Acting in the Central Nervous System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Proton Magnetic Resonance Spectroscopy Changes After Antipsychotic Treatment
Current Medicinal Chemistry Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway
Current Nanoscience Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism Cellular Actions of Gabapentin and Related Compounds on Cultured Sensory Neurones
Current Neuropharmacology Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development
Current Molecular Pharmacology Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Bioactive Loaded Lipid-based Nanostructures: A Novel Insight for Age-related Neurodegeneration
Current Molecular Medicine Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry